The Value of Radiotherapy in the Oligometastatic Non-squamous Non-small Cell Lung Cancer With Clinical Benefits From Erlotinib as Second-line Treatment (ROLE)
The Value of Radiotherapy in the Oligometastatic Non-squamous Non-small Cell Lung Cancer With Clinical Benefits From Erlotinib as Second-line Treatment: a Randomized Controlled Phase II Clinical Trial
Sponsor: Anhui Medical University
Listed as NCT01796288, this PHASE2 trial focuses on Non Small Cell Lung Cancer, Oligometastatic and remains ongoing. Sponsored by Anhui Medical University, it has been updated 6 times since 2012, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Unknown Status PHASE2
-
Oct 2017 — Jun 2018 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
▶ Show 1 earlier version
-
Jan 2017 — Oct 2017 [monthly]
Recruiting PHASE2
First recorded
Oct 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Anhui Medical University
- Anhui Provincial Hospital
- Fudan University
- Shanghai Chest Hospital
- Shanghai Pulmonary Hospital, Shanghai, China
- Wu Jieping Medical Foundation
- Wuxi No. 4 People's Hospital
- Zhejiang Cancer Hospital
For direct contact, visit the study record on ClinicalTrials.gov .